TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Acquired by Great Point Partners LLC

Great Point Partners LLC increased its position in TScan Therapeutics, Inc. (NASDAQ:TCRX) by 8.0% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 1,016,375 shares of the company’s stock after acquiring an additional 75,544 shares during the period. TScan Therapeutics comprises about 1.5% of Great Point Partners LLC’s holdings, making the stock its 23rd biggest position. Great Point Partners LLC’s holdings in TScan Therapeutics were worth $5,062,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Dimensional Fund Advisors LP acquired a new position in shares of TScan Therapeutics in the second quarter valued at approximately $70,000. The Manufacturers Life Insurance Company acquired a new position in shares of TScan Therapeutics in the second quarter valued at approximately $90,000. SG Americas Securities LLC acquired a new position in shares of TScan Therapeutics in the third quarter valued at approximately $78,000. American Century Companies Inc. increased its position in TScan Therapeutics by 48.9% during the second quarter. American Century Companies Inc. now owns 47,481 shares of the company’s stock worth $278,000 after purchasing an additional 15,596 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in TScan Therapeutics by 1.1% during the first quarter. Vanguard Group Inc. now owns 1,808,152 shares of the company’s stock worth $14,357,000 after purchasing an additional 20,000 shares during the last quarter. Institutional investors and hedge funds own 82.83% of the company’s stock.

TScan Therapeutics Stock Performance

Shares of NASDAQ:TCRX opened at $4.64 on Wednesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56. TScan Therapeutics, Inc. has a one year low of $3.92 and a one year high of $9.69. The business’s 50-day simple moving average is $5.12 and its 200 day simple moving average is $6.28. The company has a market cap of $247.64 million, a P/E ratio of -4.38 and a beta of 0.79.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.03. The firm had revenue of $1.05 million for the quarter, compared to the consensus estimate of $2.86 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. On average, sell-side analysts forecast that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current fiscal year.

Insider Buying and Selling at TScan Therapeutics

In other news, Director Barbara Klencke purchased 5,000 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The stock was acquired at an average cost of $5.29 per share, for a total transaction of $26,450.00. Following the completion of the purchase, the director now owns 45,000 shares of the company’s stock, valued at approximately $238,050. This trade represents a 12.50 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.76% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

TCRX has been the subject of several research analyst reports. Wedbush reaffirmed an “outperform” rating and set a $10.00 price target on shares of TScan Therapeutics in a research report on Tuesday, November 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of TScan Therapeutics in a research report on Tuesday, November 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of TScan Therapeutics in a research report on Friday, November 15th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, TScan Therapeutics presently has an average rating of “Buy” and a consensus target price of $12.00.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.